{"brief_title": "TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium", "brief_summary": "Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium", "condition": ["Bladder Neoplasms", "Ureteral Neoplasms", "Urethral Neoplasms", "Carcinoma, Transitional Cell"], "intervention_type": ["Drug"], "intervention_name": ["TOCOSOL Paclitaxel"], "criteria": "Inclusion Criteria: - Histologic diagnosis of transitional cell carcinoma (TCC) of the urothelium including bladder, renal pelvis, ureter, or urethra - Stage IV disease - One and only one prior systemic cytotoxic chemotherapy regimen administered as adjuvant or neoadjuvant chemotherapy or to treat locally advanced or metastatic disease - Adequate hematologic function (ANC >/= 1500 cells/mm3 & platelet count >/= 100,000/mm3) - Serum creatinine </= 2.0 mg/dL - Total bilirubin </= 1.5 mg/dL - SGOT & SGPT </= 3 times upper limit of institutional normal values - PT (INR) & PTT within institutional lab normal range - Karnofsky performance status of 60-100% - At least one unidimensionally measurable lesion, suitable for radiographic evaluation of disease response, consistent with RECIST criteria - Signed IRB/EC approved Informed Consent - Life expectancy of at least 12 weeks - 18 years of age or older - Fully recovered from any previous surgery - Not pregnant and willing to use a medically effective form of contraception during periods of chemotherapy treatment (both males and and females) - Agree not to take vitamin E supplementation while receiving study medication - Willing to participate in requested follow-up evaluations - Willing to permit treating physicians to provide information to Sonus regarding disease status and survival for 2 years after first dose of study drug Exclusion Criteria: - Prior taxane-containing chemotherapy including Taxol(R) (paclitaxel) or generic equivalent, or Taxotere(R) (docetaxel) - Peripheral neuropathy NCI-CTC grade 2 or greater - Wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of first dose, or mitomycin or nitrosoureas within 6 weeks of first dose, of study drug - An investigational agent within 4 weeks of first dose of study drug - Concurrent anticonvulsants known to induce P450 isoenzymes - Patients who are pregnant or lactating - A history of carcinoma of another primary site (other than non-melanoma skin cancers or carcinoma-in-situ of the cervix) within the previous 5 years, unless metastatic disease has been biopsied and documented to be TCC - Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of metastatic TCC - Brain metastasis - Active bowel obstruction - Active, serious infection or other serious medical problems (other than TCC) likely to impair completion of the study protocol", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Carcinoma", "Neoplasms", "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Ureteral Neoplasms", "Urethral Neoplasms", "Paclitaxel", "Albumin-Bound Paclitaxel"], "id": "NCT00077688"}